Perspective Therapeutics updates 212Pb pipeline presentation; highlights NET/melanoma/FAP data targeting $45B market

Perspective Therapeutics, Inc.

Perspective Therapeutics updates corporate presentation for 212Pb radiopharma pipeline targeting a combined $45B+ solid tumor market.
VMT-α-NET (SSTR2+ NETs): Phase 1/2a ASCO 2026 data shows durable disease control across all doses; safety profile from n=68 treated patients.
VMT01 (melanoma/MC1R): preliminary anti-tumor activity at 3.0 mCi in Phase 1/2a; synergy with immune checkpoint inhibitors highlighted.
PSV359 (FAP-ɑ) shows improved tumor retention in Phase 1/2a solid tumors; CCK2R81 in medullary thyroid cancer; data expected across programs in 2026.
Platform supports direct-to-hospital delivery with regional 212Pb manufacturing and IP portfolio covering radiopharmaceutical value chain.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.